Dimethyl fumarate for treatment of multiple sclerosis: Mechanism of action, effectiveness, and side effects

Current Neurology and Neuroscience Reports

Volumn 13, Issue 11, 2013, Pages

  Linker, Ralf A ^a   Gold, Ralf ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

Author keywords

Clinical trial; Dimethyl fumarate; Effectiveness; Immunotherapy; Multiple sclerosis; Neuroinflammation; Neuroprotection; Oral; Side effects

Indexed keywords

FUMADERM; FUMARIC ACID DERIVATIVE; FUMARIC ACID DIMETHYL ESTER; FUMARIC ACID ESTER; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; IMMUNOSUPPRESSIVE AGENT;

ABDOMINAL PAIN; ANTIOXIDANT ACTIVITY; ARTICLE; CELL PROTECTION; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL IRRITATION; HOT FLUSH; HUMAN; IMMUNOMODULATION; MULTIPLE SCLEROSIS; NAUSEA; NONHUMAN; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEINURIA; PSORIASIS; RELAPSE; TRANSIENT FLUSHING; VOMITING; ANIMAL; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL (TOPIC); GASTROINTESTINAL DISEASE; IMMUNOLOGY; METABOLISM; METHODOLOGY; REVIEW; TREATMENT OUTCOME; CHEMICALLY INDUCED; PROCEDURES;

ANIMALS; CLINICAL TRIALS AS TOPIC; FUMARATES; GASTROINTESTINAL DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; TREATMENT OUTCOME;

EID: 84893062631     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-013-0394-8     Document Type: Article

References (49)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343:938-52.
2. van Horssen J, Witte ME, Schreibelt G, de Vries HE. Radical changes in multiple sclerosis pathogenesis. Biochim Biophys Acta. 1812;2011: 141-50.
3. Rieckmann P, Toyka KV. Escalating immunotherapy of multiple sclerosis. Austrian-German-Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG]. Eur Neurol. 1999;42:121-7.
4. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon Beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998;352:1498-1504.
5. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39:285-94. (Pubitemid 26100751)
6. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase IIImulticenter, double-blind, placebo-controlled trial. Neurology. 2001;57:16-24.
7. Gold R, Linker RA, Stangel M. Fumaric acid and its esters: An emerging treatment for multiple sclerosis with antioxidative mechanism of action. Clin Immunol. 2012;142:44-8.
8. Litjens NHR, Burggraaf J, van Strijen E, van Gulpen C, Mattie H, Schoemaker RC, et al. Pharmacokinetics of oral fumarates in healthy subjects. Br J Clin Pharmacol. 2004;58:429-32.
9. Werdenberg D, Joshi R, Wolffram S, Merkle HP, Langguth P. Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters. Biopharm Drug Dispos. 2003;24:259-73. (Pubitemid 37160613)
10. Hoxtermann S, Nuchel C, Altmeyer P. Fumaric acid esters suppress peripheral CD4- And CD8-positive lymphocytes in psoriasis. Dermatology. 1998;196:223-30. (Pubitemid 28139451)
11. Treumer F, Zhu K, Glaser R, Mrowietz U. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol. 2003;121:1383-8. (Pubitemid 38005490)
12. de Jong R, Bezemer AC, Zomerdijk TP, van de Pouw-Kraan T, Ottenhoff TH, Nibbering PH. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol. 1996;26:2067-74. (Pubitemid 26297503)
13. Ockenfels HM, Schultewolter T, Ockenfels G, Funk R, GoosM. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br J Dermatol. 1998;139:390-5. (Pubitemid 28430453)
14. Asadullah K, Schmid H, FriedrichM, Randow F, Volk HD, SterryW, et al. Influence of monomethylfumarate on monocytic cytokine formation- explanation for adverse and therapeutic effects in psoriasis Arch Dermatol Res. 1997;289:623-30. (Pubitemid 27510826)
15. Ghoreschi K, Bruck J, Kellerer C, DengC, PengH, Rothfuss O, et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med. 2011;208:2291-303. This describes recent work on immunomodulatory actions of dimethyl fumarate.
16. LitjensNH, Rademaker M, Ravensbergen B, ReaD, van der PlasMJ, Thio B, et al.Monomethylfumarate affects polarization of monocytederived dendritic cells resulting in down-regulated Th1 lymphocyte responses. Eur J Immunol. 2004;34:565-75. (Pubitemid 39255966)
17. Zhu K, Mrowietz U. Inhibition of dendritic cell differentiation by fumaric acid esters. J Invest Dermatol. 2001;116:203-8. (Pubitemid 32173722)
18. Lin SX, Lisi L, Dello RC, Polak PE, Sharp A, Weinberg G, et al. The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. ASN Neuro. 2011;3(2):e00055.
19. Wierinckx A, Breve J, Mercier D, Schultzberg M, Drukarch B, Van Dam AM. Detoxication enzyme inducers modify cytokine production in rat mixed glial cells. J Neuroimmunol. 2005;166:132-43. (Pubitemid 41074663)
20. Loewe R, Holnthoner W, Groger M, Pillinger M, Gruber F, Mechtcheriakova D, et al. Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kB/p65 in human endothelial cells. J Immunol. 2002;168:4781-7. (Pubitemid 34441387)
21. Stoof TJ, Flier J, Sampat S, Nieboer C, Tensen CP, Boorsma DM. The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells. Br J Dermatol. 2001;144:1114-20. (Pubitemid 34204199)
22. Vandermeeren M, Janssens S, BorgersM, Geysen J.Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem Biophys Res Commun. 1997;234:19-23. (Pubitemid 27267523)
23. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain. 2006;129:1953-71. (Pubitemid 44289062)
24. Herrero-Herranz E, Pardo LA, Gold R, Linker RA. Pattern of axonal injury in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Neurobiol Dis. 2008;30:162-73.
25. Schilling S, Goelz S, Linker R, Luehder F, Gold R. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol. 2006;145:101-7. (Pubitemid 43893938)
26. Linker RA, Lee DH, Ryan S, Van Dam AM, Conrad R, Bista P, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain. 2011;134:678-92. This is a preclinical study revealing that dimethyl fumarate activates the Nrf2 antioxidant pathway.
27. van Muiswinkel FL, Kuiperij HB. The Nrf2-ARE signalling pathway: promising drug target to combat oxidative stress in neurodegenerative disorders. Curr Drug Targets CNS Neurol Disord. 2005;4:267-81. (Pubitemid 40754162)
28. Liu Y, Kern JT, Walker JR, Johnson JA, Schultz PG, Luesch H. A genomic screen for activators of the antioxidant response element. Proc Natl Acad Sci U S A. 2007;104:5205-10. (Pubitemid 47186200)
29. Albrecht P, Bouchachia I, Goebels N, Henke N, Hofstetter HH, Issberner A, et al. Effects of dimethyl fumarate on neuroprotection and immunomodulation. J Neuroinflammation. 2012;9:163.
30. Scannevin RH, Chollate S, Jung MY, Shackett M, Patel H, Bista P, et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther. 2012;341:274-84. This describes comprehensive in vitro work on the cytoprotective role of FAE.
31. van Horssen J, Drexhage JA, Flor T, Gerritsen W, van der Valk P, de Vries HE. Nrf2 and DJ1 are consistently upregulated in inflammatory multiple sclerosis lesions. Free Radic Biol Med. 2010;49:1283-9.
32. Schweckendiek W. Treatment of psoriasis vulgaris.Med Monatsschr. 1959;13:103-4.
33. Mrowietz U, Christophers E, Altmeyer P. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German multicentre study. Br J Dermatol. 1998;138:456-60. (Pubitemid 28145514)
34. Mrowietz U, Christophers E, Altmeyer P. Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. Br J Dermatol. 1999;141:424-9. (Pubitemid 29448401)
35. Altmeyer P, Hartwig R, Matthes U. DasWirkungs- und Sicherheitsprofil von Fumarsäureestern in der oralen Langzeittherapie bei schwerer therapieresistenter Psoriasis vulgaris. Eine Untersuchung an 83 Patienten. Hautarzt. 1996;47:190-6. (Pubitemid 26117567)
36. Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N Engl J Med. 2013;368:1657-8.
37. van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP. PML in a patient treated with dimethyl fumarate froma compounding pharmacy. N Engl J Med. 2013;368:1658-9.
38. SweetserMT, Dawson KT, Bozic C. Manufacturer's response to case reports of PML. N Engl J Med. 2013;368:1659-61.
39. Schwab N, Ulzheimer JC, Fox RJ, Schneider-Hohendorf T, Kieseier BC, Monoranu CM, et al. Fatal PML associated with efalizumab therapy: insights into integrin aLb2 in JC virus control. Neurology. 2012;78:458-67.
40. Schimrigk S, Brune N, Hellwig K, Lukas C, Bellenberg B, Rieks M, et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: An open-label, baseline-controlled pilot study. Eur J Neurol. 2006;13:604-10. (Pubitemid 43873632)
41. Kappos L, Gold R, Miller DH, MacManus DG, Havrdova E, Limmroth V, et al. Efficacy and safety of oral fumarate in patients with relapsingremitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;372:1463-72.
42. Kappos L, Gold R, Miller DH, MacManus DG, Havrdova E, Limmroth V, et al. Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study. Mult Scler. 2012;18:314-21.
43. MacManus DG, Miller DH, Kappos L, Gold R, Havrdova E, Limmroth V, et al. BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. J Neurol. 2011;258:449-56. This provides MRI evidence for a tissueprotective effect of the dimethyl fumarate preparation BG-12 in RRMS.
44. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098-107. This is a pivotal phase III study of the dimethyl fumarate preparation BG-12 in RRMS.
45. Fox RJ, Miller DH, Phillips JT, HutchinsonM, Havrdova E, Kita M, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl JMed. 2012;367:1087-97. This is a pivotal phase III study of the dimethyl fumarate preparation BG-12 in RRMS.
46. Bar-Or A, Gold R, Kappos L, Arnold DL, Giovannoni G, Selmaj K, et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol. 2013. doi:10.1007/s00415-013-6954-7.
47. HutchinsonM, Fox RJ, Miller DH, Phillips JT, Kita M, Havrdova E, et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J Neurol. 2013. doi:10.1007/s00415-013-6968-1.
48. Ellrichmann G, Petrasch-Parwez E, Lee DH, Reick C, Arning L, Saft C, et al. Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease. PLoS One. 2011;6:e16172.
49. Johnson JA, Johnson DA, Kraft AD, Calkins MJ, Jakel RJ, VargasMR, et al. The Nrf2-ARE pathway: An indicator and modulator of oxidative stress in neurodegeneration. Ann N YAcad Sci. 2008;1147:61-9.